

We realize that, under our approach subsequent to the March 2024 notice, providers may have submitted information pertaining to this data element to the NPPES; this notice makes providers aware how that data will be treated going forward. In this section, we discuss our prospective approach to the data element, how the previously collected data will be stored and disseminated, and providers' options for updating data elements previously submitted to the provider enumeration system.

The data element relevant to this notice is listed in Table 1, along with the descriptions of the information contained in each column of Table 1 are as follows:

- *Data Element Name*: The name of the data element residing in the NPPES.
- *Description*: The definition of the data element and related information.

- *Data Status*: The instruction for furnishing the information requested for the data element. The abbreviations used in this column are as follows:

- ++ *Required (R)*: Required for NPI assignment.
- ++ *NPPES-generated (NG)*: Generated or assigned by the NPPES.
- ++ *Optional (O)*: Not required for NPI assignment.
- ++ *Situational (S)*: If a certain condition exists, the data element is required. Otherwise, it is not required.
- ++ *Repeat (RPT)*: Indicates that the data element is a repeating field. A repeating field is one that can accommodate more than one separate entry. Each separate entry must meet the edits, if any, designated for that data element.
- *Data Condition*: Describes the condition(s) under which a "Situational" data element must be furnished.

- *Entity Types*: The "Entity type codes" to which the data element applies. Code describing the type of health care provider that is being assigned an NPI. Codes are as follows:

- ++1 = (Person): individual human being who furnishes health care.
- ++2 = (Non-person): entity other than an individual human being that furnishes health care (for example, hospital, SNF, hospital subunit, pharmacy, or HMO).
- *Use*: The purpose for which the information is being collected or will be used. The abbreviations used in this column are as follows:
 - ++I: The data element supports the unique identification of a health care provider.
 - ++A: The data element supports administrative implementation specification.

TABLE 1—NPPES DATA ELEMENT AT ISSUE IN THIS NOTICE

Data element name	Description	Data status	Data condition	Entity types	Use
Provider sex code.	The code designates the provider's sex if the provider is a person.	O	Collected if the provider's NPI is Entity type code = 1; submission of a missing or blank value will not cause an application to be rejected.	1	I

The NPI final rule identified provider gender code as a required data element if the provider's NPI is Entity type code = 1. While neither the NPI final rule nor the NPPES Data Dissemination notice identified the gender codes that NPPES would collect and disseminate when an individual provider applied for an NPI, providers were given the option to click on a box that captured gender as either male or female. NPPES stored that selection as code (F) when an individual selected female and (M) when an individual selected male. The NPI Registry query-only database displayed the descriptions "Male" and "Female" in disseminating the provider gender information, and NPI downloadable files displayed the information using the codes (M) and (F).

NPPES will disseminate sex code options of M and F to promote improved accuracy in publicly available data. Provider gender code selections made after March 4, 2024, that are no longer available in accordance with the Defending Women E.O. will now appear as blank (that is, will have no value selected) in public facing files. Although the provider sex code is collected on the NPI application when a provider indicates their entity type is "1," it will now be an optional data element. For clarity, we emphasize that an applicant who is an individual (Entity type code

= 1) may leave the data field empty (doing so will not affect an applicant's ability to enumerate), and this data element will no longer fall within the contours of 45 CFR 162.410(a)(4), which requires reporting to the NPPES changes to required data elements within 30 days of the change. Providers with Entity type code = 1 who previously furnished to NPPES a provider gender code other than M or F in accordance with the March 4, 2024 notice (89 FR 15581) may elect to update or change their selection in NPPES to align with the new provider sex code's parameters (or have the EFIO that submitted their NPI application data to NPPES cause them to be changed in NPPES) or they may elect to do nothing, in which case the sex code field will appear as blank in public facing files.

III. Collection of Information Requirements

This document does not impose any new information collection, recordkeeping requirements, or budgetary changes. The information collection request for these NPPES data is currently approved under OMB

control number 0938–0931 and expires March 31, 2028.

Robert F. Kennedy, Jr.
 Secretary, Department of Health and Human Services.

[FR Doc. 2025–14478 Filed 7–30–25; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel PAR–21–321: Cancer Center Support Grants.

Date: September 16–17, 2025.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Eun Ah Cho, Ph.D., Scientific Review Officer, Cancer Diagnosis, Prevention & Therapeutics (CDPT), Center for Scientific Review, National Cancer Institute, NIH, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 496–3591, choe@mail.nih.gov.

Name of Committee: Emerging Technologies and Training Neurosciences Integrated Review Group: Molecular Neurogenetics Study Section.

Date: October 2–3, 2025.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Prithi Rajan, Ph.D., Scientific Review Officer, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., 5th Floor, MSC 9531, Bethesda, MD 20892, prithi.rajan@nih.gov.

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group: Digestive and Nutrient Physiology and Diseases Study Section.

Date: October 9–10, 2025.

Time: 8:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Aster Juan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20817, 301–435–5000, juana2@mail.nih.gov.

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group: Kidney and Urological Systems Function and Dysfunction Study Section.

Date: October 9–10, 2025.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Santanu Banerjee, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2106, Bethesda, MD 20892 (301) 435–5947, banerjees5@mail.nih.gov.

Name of Committee: Oncology 2—Translational Clinical Integrated Review Group: Therapeutic Immune Regulation Study Section.

Date: October 9–10, 2025.

Time: 9:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Yue Wu, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 803C, Bethesda, MD 20892 (301) 867–5309, wuy25@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 29, 2025.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–14512 Filed 7–30–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center For Scientific Review; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Clinical Neuroplasticity and Neurotransmitters.

Date: August 26, 2025.

Time: 10:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Suzan Nadi, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5217B, MSC 7846, Bethesda, MD 20892, (301) 435–1259, nadis@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 28, 2025.

Sterlyn H Gibson

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2025–14453 Filed 7–30–25; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA–2025–0013; OMB No. 1660–0086]

Agency Information Collection Activities: Proposed Collection, Comment Request; National Flood Insurance Program—Ask the Advocate Web Form

AGENCY: Federal Emergency Management Agency (FEMA), Department of Homeland Security (DHS).

ACTION: Notice; correction.

SUMMARY: On Friday, June 6, 2025, FEMA published in the **Federal Register** a 60-Day notice of revision and request for comments for an information collection concerning the Office of the Flood Insurance Advocate’s (OFIA) Ask the Advocate web form and the removal of two instruments that are no longer needed. This notice provides a correction to this information to be used in lieu of the information published June 6, 2025.

DATES: This correction is effective July 31, 2025.

ADDRESSES: To avoid duplicate submissions to the docket, please submit comments at <http://www.regulations.gov> under Docket ID FEMA–2025–0013. Follow the instructions for submitting comments.

All submissions received must include the Agency name and Docket ID. Regardless of the method used to submitting comments or material, all submissions will be posted, without change, to the Federal eRulemaking Portal at <http://www.regulations.gov>, and will include any personal information you provide. Therefore, submitting this information makes it public. You may wish to read the Privacy and Security Notice that is available via a link on the homepage of <http://www.regulations.gov>.

FOR FURTHER INFORMATION CONTACT: Joe Cecil, Advocate Representative Team Lead, Office of the Flood Insurance Advocate, National Flood Insurance Program, Federal Emergency Management Agency, at (202) 701–3475